Evidence map›Paper›PMID 36367613›Full record

ArticleAIDS and behavior2023

Impact of COVID-19 & Response Measures on HIV-HCV Prevention Services and Social Determinants in People Who Inject Drugs in 13 Sites with Recent HIV Outbreaks in Europe, North America and Israel.

Lucas Wiessing, V Sypsa, A O Abagiu, A Arble, N Berndt, A Bosch, S Buskin, D Chemtob, B Combs, C Conyngham and 22 more

Open access · bronzeAbstract read
In one paragraph

Article in AIDS and behavior, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 18 institutions in 9 countries.

Lucas WiessingPublic Health Unit, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Praça Europa 1, Cais do Sodré, 1249-289, Lisbon, Portugal. lucas.wiessing@emcdda.europa.eu.ORCID http://orcid.org/0000-0002-2078-2826
V SypsaDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
A O AbagiuNational Institute for Infectious Diseases, Bucharest, Romania.
A ArbleHamilton County Public Health, Cincinnati, OH, USA.
N BerndtLuxembourg National Focal Point of the European Monitoring Centre for Drugs and Drug Addiction, Department of Epidemiology and Statistics, Directorate of Health, Luxembourg-Hamm, Luxembourg.
A BoschSTD, HIV, and TB Section - Infectious Disease Epidemiology, Prevention and Control, Minnesota Department of Health, St. Paul, MN, USA.
S BuskinUniversity of Washington, Seattle, WA, USA.
D ChemtobDepartment of Tuberculosis and AIDS, Ministry of Health, Jerusalem, Israel.
B CombsScott County Health Department, Scottsburg, IN, USA.
C ConynghamPhiladelphia Department of Public Health, Philadelphia, PA, USA.
J FeelemyerSchool of Global Public Health, New York University, New York, NY, USA.
M FitzgeraldNational Social Inclusion Office, Health Services Executive, Dublin, Ireland.
D GoldbergPublic Health Scotland, Glasgow, Scotland, United Kingdom.
A HatzakisDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
R E PatrascuNational Institute for Infectious Diseases, Bucharest, Romania.
E KeenanNational Social Inclusion Office, Health Services Executive, Dublin, Ireland.
I KhanFirst Nations and Inuit Health Branch, Indigenous Services Canada, Regina, Canada.
S KonradFirst Nations and Inuit Health Branch, Indigenous Services Canada, Regina, Canada.
J LeahyOregon Health Authority, Portland, OR, USA.
A McAuleyPublic Health Scotland, Glasgow, Scotland, United Kingdom.
T MenzaOregon Health Authority, Portland, OR, USA.
S MerrickHamilton County Public Health, Cincinnati, OH, USA.
R MetcalfeSchool of Health and Life Sciences, Glasgow Caledonian University, Glasgow, Scotland, United Kingdom.
T RademakerHamilton County Public Health, Cincinnati, OH, USA.
S RevivoIzhar Needle and Syringe Programme, Public Health Association, Jerusalem, Israel.
P RoscaDepartment for the Treatment of Substance Abuse, Ministry of Health, Jerusalem, Israel.
C Seguin-DevauxDepartment of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.
S SkinnerUniversity of Saskatchewan, Saskatoon, Canada.
C SmithPhiladelphia Department of Public Health, Philadelphia, PA, USA.
J TinsleyPublic Health - Seattle & King County, Seattle, WA, USA.
M WilbergMinnesota Department of Human Services, St. Paul, Minnesota, USA.
D Des JarlaisSchool of Global Public Health, New York University, New York, NY, USA.
Hamilton County Coroner · USGlasgow Caledonian University · GBHealth Service Executive · IEIndigenous Services CanadaNational and Kapodistrian University of Athens · GRNational Institute of Research and Development for Biological Sciences · RONew York University · USOregon Health Authority · USPhiladelphia Department of Public Health · USPublic Health – Seattle & King County · USEuropean Monitoring Centre for Drugs and Drug Addiction · PTHebrew University of Jerusalem · ILIsrael Ministry of Health · ILLuxembourg Institute of Health · LUMinnesota Department of Health · USMinnesota Department of Human Services · USPublic Health Scotland · GBUniversity of Saskatchewan · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HIV/HCV prevention among people who inject drugs (PWID) is of key public health importance. We aimed to assess the impact of COVID-19 and associated response measures on HIV/HCV prevention services and socio-economic status of PWID in high-HIV-risk sites. Sites with recent (2011-2019) HIV outbreaks among PWID in Europe North America and Israel, that had been previously identified, were contacted early May 2020. Out of 17 sites invited to participate, 13 accepted. Semi-structured qualitative site reports were prepared covering data from March to May 2020, analyzed/coded and confirmed with a structured questionnaire, in which all sites explicitly responded to all 103 issues reported in the qualitative reports. Opioid maintenance treatment, needle/syringe programs and antiretroviral treatment /hepatitis C treatment continued, but with important reductions and operational changes. Increases in overdoses, widespread difficulties with food and hygiene needs, disruptions in drug supply, and increased homelessness were reported. Service programs rapidly reformed long established, and politically entrenched, restrictive service delivery policies. Future epidemic control measures should include mitigation of negative side-effects on service provision and socio-economic determinants in PWID.

Indexed as

COVID-19Drug UsersHepatitis CHIV InfectionsSubstance Abuse, IntravenousDisease OutbreaksEuropeHepacivirusHumansIsraelPharmaceutical PreparationsSocial Determinants of HealthPharmaceutical PreparationsCOVID-19EpidemiologyHepatitis CHIVHomelessnessOutbreaksOverdosePeople who inject drugs (PWID)PreventionServicesSocial determinantsTreatment

Identifiers

PMID36367613
PMCPMC9651099
OpenAlexW4308770266

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.